Impact Events
Cannabis Suisse Corp. Swings to Net Income, but Faces Going Concern Warning
Cannabis Suisse Corp. reported a net income of $122,739 for the fiscal year ended May 31, 2026, a substantial turnaround from a net loss of $456,142 in the previous year. This improvement was largely driven by a significant increase in 'Other Income' due to the absence of a large debt settlement loss recorded in the prior year. However, the company's core rental operations generated a gross loss of $931 for the year, with rental revenue of $21,000. Despite the net income, the company's financial position remains precarious, with a substantial working capital deficit and a 'going concern' warning from its auditors, highlighting its dependence on related-party funding and the need for additional capital to continue operations.
ArcelorMittal Halts Kryvyi Rih Operations After Missile Strikes; $1B Impairment Expected
ArcelorMittal announced it is unable to safely and sustainably restart operations at its ArcelorMittal Kryvyi Rih subsidiary in Ukraine following multiple recent missile strikes. The plant has been targeted by four missile strikes over the past five weeks, resulting in five fatalities and 17 injuries among employees. The company is discussing the future of the plant with the Government of Ukraine and expects to record a non-cash impairment charge of approximately US$1 billion. ArcelorMittal has provided over US$700 million to the subsidiary since the start of the war.
Galaxy Gaming Amends Credit Agreement, Increases CapEx Limit
Galaxy Gaming, Inc. has entered into a Second Amendment to its Credit Agreement with BMO Bank N.A. The amendment increases the annual capital expenditure limitation to 10% of the prior year's net revenue and allows for a one-time EBITDA addback of $505,361. This addback is specifically for determining compliance with certain financial ratios and relates to state sales/use tax assessments recognized in the second quarter of 2026. The adjustments will be applicable for the four quarters following the quarter ended June 30, 2026.
Siebert Financial Corp. Announces Board Changes
Siebert Financial Corp. announced changes to its Board of Directors. Gloria E. Gebbia resigned from the Board on September 22, 2026, to focus on public relations and philanthropic endeavors. Her resignation was not due to any disagreement with the Company. Concurrently, the Board appointed John M. Gebbia to fill the vacancy. Mr. John M. Gebbia has extensive experience in the brokerage industry and currently serves as Co-Chief Executive Officer of Muriel Siebert & Co., LLC, a subsidiary of the Company.
SEALSQ Corp Updates Post-Quantum Semiconductor Certification Timelines
SEALSQ Corp has updated its post-quantum semiconductor certification timelines due to regulatory and technical developments. The company now expects the QS7001 V1 Hardware Common Criteria Evaluation Test Report in October 2026 and the QS7001 V2 full PQC Test Report in January 2027. For the QVault Trusted Platform Module, TCG certification for TPM-183 is targeted for February 2027, and for TPM-185 in May 2027. All product versions are currently available as engineering samples.
Johnson Outdoors Declares Quarterly Cash Dividend
Johnson Outdoors Inc. announced that its Board of Directors has approved a quarterly cash dividend. The dividend amounts are $0.33 per Class A share and $0.30 per Class B share. This dividend will be paid on October 23, 2026, to shareholders who are on record as of the close of business on October 9, 2026. The company also provided standard safe harbor statements regarding forward-looking information.
Aeternum Health Acquires ARM, Securing Nkamouna Nickel-Cobalt Project
Aeternum Health, Inc. has acquired 100% of American Renaissance Minerals LLC (ARM), the entity advancing the Nkamouna Nickel-Cobalt mining project in Cameroon. The acquisition involves issuing up to 133,333,333 pre-split shares or pre-funded warrants to American Renaissance Resources LLC (ARR). ARR will receive observer rights to Aeternum's Board meetings under certain conditions. This move consolidates a previous option agreement into direct ownership, simplifying project advancement as ARM works with the Cameroonian government towards a new mining permit.
Braskem SA Informed of Bankruptcy Court Decision on Reorganization
Braskem S.A. has been informed of a decision from the 2nd Bankruptcy and Judicial Reorganization Court of São Paulo concerning its extrajudicial reorganization proceedings. The company has not yet received formal notification of the decision, which awaits official publication. Braskem is currently evaluating the implications and determining the subsequent actions, and will provide further updates to the market as material developments occur. The full decision document is accessible through a provided link.
BiomX Subsidiary Eyes 51% Stake in RT LTA Systems via Option Deal
BiomX Inc. announced that its wholly owned subsidiary, Tessera Israel, has entered into an Option Agreement with X S.E. Security and Defense Ltd. to potentially acquire 51% of RT LTA Systems Ltd., a developer of tethered aerostat systems. The agreement grants Tessera Israel the right, exercisable within 90 days, to purchase the shares, subject to due diligence and regulatory approvals. An initial $1,000,000 option consideration is payable, which will be credited towards the purchase price if the option is exercised. The purchase price is determined by RT's equity value, calculated as the lower of $13,000,000 or a multiple of its average EBITDA and revenue over fiscal years 2026-2028. Payment can be made in cash, BiomX common stock, or a combination. The agreement also includes a perpetual license of RT's technology to Tessera Israel.
Star Fashion Culture Holdings Prices $9.6M Share Offering
Star Fashion Culture Holdings Ltd announced the pricing of its public offering of 12,000,000 Class A ordinary shares at $0.80 per share, expecting to raise approximately $9.6 million in gross proceeds. The net proceeds are intended for developing online marketing services and for general administration and working capital. Kingswood Capital Partners, LLC served as the placement agent. The company also noted its reliance on Cayman Islands home country practices to exempt it from certain Nasdaq shareholder approval requirements related to the offering.
First Seacoast Bancorp Merger Receives Final Regulatory Approvals
First Seacoast Bancorp, Inc. announced that it has received the final regulatory approvals and waivers necessary to complete its merger with Cambridge Financial Group, Inc. and the merger of First Seacoast Bank with and into Cambridge Savings Bank. The company's stockholders had previously approved these transactions at a special meeting held on August 27, 2026. The closing of the merger is anticipated to take place on October 1, 2026, contingent upon the fulfillment of standard closing conditions.
Aquestive Therapeutics Resubmits Anaphylm NDA to FDA
Aquestive Therapeutics, Inc. has filed an 8-K report detailing an investor presentation. The company announced the resubmission of its New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film to the FDA on September 17, 2026, following a Complete Response Letter (CRL) received earlier in the year. The presentation also highlights the company's pipeline, including AQST-108 for atopic dermatitis, and its financial position, with $98.5 million in cash and access to additional funding upon Anaphylm's potential FDA approval. Key product attributes and market opportunities for Anaphylm and AQST-108 are discussed.
Quantum Cyber Sharpens Focus on Quantum Navigation, Drones, US Manufacturing
Quantum Cyber N.V. announced a sharpened strategic focus on Quantum Navigation, Interceptor Drones, and U.S. Manufacturing, presenting an updated investor presentation. The company's strategy is centered on a 'System-of-Systems' thesis for GPS-deficient, autonomous warfare, with key product pillars including the Quantum Antenna, one-way attack/interceptor drones, and the MAHCA operating system. Manufacturing operations are anchored at a facility in Bridgeport, Connecticut, with a 3D printing drone production farm now operational, targeting a future annual capacity of 100,000 drones.
C4 Therapeutics Presents Positive Biomarker Data for Cemsidomide in Multiple Myeloma Trials
C4 Therapeutics presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone and preliminary biomarker data from its Phase 1b trial of cemsidomide in combination with elranatamab. The data demonstrate cemsidomide's immunomodulatory activity, showing robust T-cell activation and expansion, and prevention of T-cell exhaustion. The 75 µg dose level in the Phase 1b trial was declared safe, and the trial is advancing to dose escalation and expansion cohorts. Data from all cohorts are expected in mid-2027.
Baidu Continues Share Repurchases in September 2026
Baidu, Inc. filed a Form 6-K reporting its Next Day Disclosure Return for September 24, 2026. The filing details a series of share repurchases conducted throughout September 2026. The company repurchased shares on multiple dates, with the number of shares bought back ranging from 541,200 to 576,400 per day, at prices generally between HKD 86.73 and HKD 92.38. The total number of issued shares remained unchanged at 2,209,541,178 as of September 24, 2026, indicating that the repurchased shares were either not yet cancelled or were part of ongoing buyback programs.